A retrospective, multicentrestudy of perampanel given as monotherapy in routine clinical care in people with epilepsy

Antonio Gil-Nagela, Sergey Burdb, Manuel Toledoc, JosemirW.Sanderd,e,f, Anna Lebedevab, Anna Patteng, Antonio Laurenzah, on behalf of the Study 504 investigator group

aHospital Ruber Internacional, Calle de la Masó 38, 28034 Madrid, Spain; bPirogov Russian National Research Medical University, Ostrovitianov str. 1, Moscow, Russia, 117997; cHospital Universitario Vall d’Hebron, Passeig de la Vall d'Hebron 119–129, 08035 Barcelona, Spain; dUCL Institute of Neurology, Queen Square, London, WC1N 3BG, UK; eChalfont Centre for Epilepsy, Chalfont St Peter, Gerrards Cross, SL9 0RJ, UK; fStichting Epilepsie Instellingen Nederland (SEIN), Achterweg 5, Heemstede, 2103 SW, The Netherlands; gEisai Ltd., European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL109SN, UK; hEisai Inc., 100 Tice Blvd, Woodcliff Lake, NJ07677, USA

Corresponding author:
Antonio Gil-Nagel
E-mail:

Supplementary Table C.1Retentionrates according to AED use, epilepsy history and time since the initiation of perampanel monotherapy(A) for individuals receiving secondary monotherapy and (B) for all individuals receiving primary or secondary monotherapy (posthoc analysis; safetyset).

ASecondary monotherapy onlya

Retention rates, n/N (%)
3 months / 6 months
Use of AEDs that were stopped prior to the initiation of perampanel
AED number
0 / 15/15 (100) / 9/12 (75)
≥1 / 29/31 (94) / 15/22 (68)
Epilepsy history
Time since epilepsy diagnosis
<10 years / 26/27 (96) / 13/20 (65)
≥10 years / 17/18 (94) / 10/13 (77)
Epilepsy syndrome
IGE / 4/5 (80) / 2/4 (50)
Focal seizures / 37/38 (97) / 20/27 (74)

BPrimary or secondary monotherapya

Retention rates, n/N (%)
3 months / 6 months
Use of AEDs that were stopped prior to the initiation of perampanel
AED number
0 / 18/18 (100) / 12/15 (80)
≥1 / 34/37 (92) / 20/28 (71)
Epilepsy history
Time since epilepsy diagnosis
<10 years / 30/31 (97) / 17/24 (71)
≥10 years / 21/23 (91) / 14/18 (78)
Epilepsy syndrome
IGE / 6/7 (86) / 4/6 (67)
Focal seizures / 43/45 (96) / 26/34 (76)

aDue to the small number of subjects, retention rate data have not been shown for months 12, 18 and 24.
AED, antiepileptic drug; IGE, idiopathic generalised epilepsy.

Supplementary Table C.2Responder rates (50%) according to AED use, epilepsy history and time period (posthoc analysis; full analysis set).

50% responder rate, n/N (%)
Last 3 months of perampanel adjunctive treatment / First 3 months of perampanel monotherapy
Use of AEDs that were stopped prior to the initiation of perampanel
AED number
0 / 11/15 (73) / 13/16 (81)
≥1 / 12/22 (55) / 19/24 (79)
AED use during adjunctive treatment (only individuals who received conversion monotherapy)
EIAEDs
EIAEDsa / 9/10 (90) / 10/10 (100)
Non-EIAEDs only / 14/27 (52) / 21/27 (78)
SCBs
SCBs onlyb / 12/16 (75) / 15/16 (94)
Partial SCBs onlyc / 4/8 (50) / 5/8 (63)
Non-SCBs only / 3/9 (33) / 7/9 (78)
Frequent AED types
Eslicarbazepine acetate / 4/4 (100) / 4/4 (100)
Lacosamide / 4/6 (67) / 4/5 (80)
Lamotrigine / 3/4 (75) / 4/4 (100)
Levetiracetam / 4/9 (44) / 9/10 (90)
Valproic acid / 3/6 (50) / 4/6 (67)
AED number
0 / N/A / 1/3 (33)
1 / 18/31 (58) / 26/31 (84)
2 / 5/6 (83) / 5/6 (83)
Epilepsy history
Time since epilepsy diagnosis
<10 years / 13/20 (65) / 19/22 (86)
≥10 years / 9/16 (56) / 12/17 (71)
Epilepsy syndromed
Focal seizuresd / 21/32 (66) / 29/35 (83)

aEIAEDs defined as: carbamazepine, eslicarbazepine acetate, oxcarbazepine, phenytoin.
bSCBs defined as: carbamazepine, eslicarbazepineacetate, lacosamide, lamotrigine, mephenytoin, oxcarbazepine, phenytoin, rufinamide.
cPartial SCBs (those AEDs that work partly via sodium-channel blockade) defined as: clobazam, clonazepam, felbamate, phenobarbital, primidone, sultiame, topiramate, valproic acid, zonisamide.

dData not shown for those with idiopathic generalised epilepsy due to very small numbers (n=3 for last 3 months of adjunctive treatment and first 3 months of monotherapy).

AED, antiepileptic drug; EIAED, enzyme-inducing antiepileptic drug; N/A, not applicable; SCB, sodium-channel blocker.

1